Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature

Chukwuka Eze*, Nina-Sophie Hegemann, Olarn Roengvoraphoj, Maurice Dantes and Farkhad Manapov

Department of Radiation Oncology, LMU Munich, Munich, Germany

Leptomeningeal metastases (LM) are found in approximately 3.8% of non-small cell lung cancer cases with an increased incidence in adenocarcinoma, and approximately one-third of patients will present with concomitant brain metastases. We report the case of a 50-year-old male patient with stage IV exon 19-del-EGFR mutant lung adenocarcinoma who progressed on second-generation TKI therapy with manifestation of symptomatic simultaneous diffuse brain and LM. Whole-brain radiotherapy with concurrent afatinib resulted in an almost complete regression of neurological symptoms as well as good, durable radiological response. Furthermore, treatment was well tolerated with no relevant adverse effects.

Keywords: afatinib, brain and leptomeningeal metastases, non-small cell lung cancer, tyrosine-kinase inhibitor, whole-brain radiotherapy

INTRODUCTION

Leptomeningeal metastases (LM) represent the infiltration of the leptomeninges by malignant cells (1) and are a readily increasing complication in cancer patients. LM are found in approximately 5% of patients with malignant tumors (1), and in non-small cell lung cancer (NSCLC), the incidence is approximately 3.8% with an increased incidence in adenocarcinoma, and roughly one-third of patients will present with concomitant brain metastases (BM) (2). The incidence is steadily increasing due to improvement in diagnostic tools such as neuroimaging methods as well as availability of improved treatments, consecutively leading to improved survival. However, general prognosis remains poor in the order of 2–4 months (3–7). Currently, no standard treatment exists (8). Occurrence of LM under prolonged tyrosine-kinase inhibitor (TKI) therapy has been previously described (9).

Afatinib is a second-generation irreversible covalent inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinases including ErbB-2 (HER2) and ErbB-4. Subgroup analysis from LUX-LUNG 3 and LUX-LUNG 6 studies demonstrated a significant overall survival benefit for afatinib compared to chemotherapy in UICC stage IIIB/IV lung adenocarcinoma patients with 19del-EGFR mutation (10). Consecutively, in a combined post hoc analysis of both studies, progression free survival was significantly improved with afatinib vs. with chemotherapy in patients with BM (8.2 vs. 5.4 months; HR, 0.50; \( p = 0.0297 \)) (11). There is a paucity of literature...
on concurrent radiotherapy and second-generation TKIs. In 2014, Atmaca et al. published a case report of a patient who received concomitant radiotherapy to the mediastinum and primary lung tumor with afatinib. The therapy resulted in partial remission in the irradiated sites without any relevant treatment-associated adverse effects (12). In addition, Li et al. reported in a case series on a 52-year-old male patient with BM from an L858R mutant adenocarcinoma of the lung. Whole-brain radiotherapy (WBRT) was delivered to a total dose of 30.0 Gy in 10 fractions, and afatinib was administered concurrently. Follow-up magnetic resonance imaging (MRI) showed regression of BM (13).

CASE

The case of a 50-year-old male never smoker with stage IV Exon 19-del-EGFR mutant, ALK- and ROS-1-negative lung adenocarcinoma diagnosed in April 2015 was presented at the multidisciplinary tumor board. At initial diagnosis, the patient presented with malignant pleural effusion and FDG-avid diffuse bone metastasis on 18F-FDG/PET-CT (positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-d-glucose integrated with computed tomography). Due to Exon-19-deletion, afatinib 40 mg/day was prescribed. Follow-up imaging showed good extracranial remission. Approximately 12 months later, the patient presented with cephalalgia, seizures, impaired vision, and hypesthesia. Gadolinium-enhanced multiplanar MRI of the brain and spine showed isolated intraparenchymal and leptomeningeal carcinomatosis of the brain; the findings were conclusive for leptomeningeal spread (see Figures 1–3). Analysis of the cerebrospinal fluid (CSF) confirmed the findings. The patient was started on oral dexamethasone. 18F-FDG-PET/CT confirmed no signs of extracranial tumor progression. The patient underwent WBRT with concurrent afatinib due to fear of extracranial tumor progression in the case afatinib was discontinued. WBRT was applied with 6 MV photon beams once daily; fourteen fractions to a total dose of 35.0 Gy and was well tolerated without any severe cutaneous adverse effects. Three-month follow-up MRI and 18F-FDG-PET/CT showed significant regression of intracranial disease as well as stable extracranial disease. Furthermore, the patient noted an almost complete regression of the above-mentioned neurological symptoms. Approximately nine months following WBRT (see Figures 1–3), contrast-enhanced MRI of the brain showed sustained durable response in the absence of any severe neurological side effects. Furthermore, follow-up 18F-FDG/PET-CT showed stable extracranial disease with multiple FDG non-avid sclerotic bone lesions as a sign of treatment response to afatinib. In addition, although there were no signs of tumor progression on the follow-up scans, after discussion at the multidisciplinary tumor board, precautionary further analysis of the CSF extracted at initial diagnosis of cranial metastases for acquired secondary T790M mutation was recommended.

DISCUSSION

Based on the National Comprehensive Cancer Network guidelines, WBRT is a mainstay in the treatment of BM. However, its role in the treatment of LM is yet to be clearly defined. Morris et al. demonstrated in a retrospective study on LM from NSCLC poor survival. In the study, survival was not improved by WBRT (14). In contrast, Soon et al. showed in a systematic review and meta-analysis that there was some evidence that upfront cranial radiotherapy might improve intracranial disease and survival outcomes compared with TKI alone in patients with EGFR mutant NSCLC (15). A recently published study by Jiang et al. demonstrated no overall survival benefit when first-generation TKIs combined with WBRT vs. TKIs alone were administered (16). Hoffknecht et al. showed that patients pretreated with first-generation TKI and new intracranial progression could benefit from treatment conversion to afatinib (17).

In the present case, simultaneous intraparenchymal brain and LM arose during afatinib therapy despite extracranial tumor control, which can be partially attributed to EGFR mutation heterogeneity (18). There has been no study focusing on the efficacy of WBRT combined with afatinib in LM, but clinical studies on BM have shown that WBRT could increase the permeability of
TKI into the CSF (19, 20); hence, in this case, response may also be partially attributed to this phenomenon. In the present case, concomitant afatinib with WBRT was feasible with achievement of rash palliation of symptoms and good, durable radiological response in an Exon19-del EGFR-mutant lung adenocarcinoma patient who progressed during TKI therapy with the manifestation of simultaneous brain and LM. Remarkably, WBRT in combination with afatinib resulted in sustained tumor control going on 9 months following treatment at a stage of disease with dismal prognosis.

ETHICS STATEMENT

This case report was carried out in accordance with the recommendations of the Ethics Committee of the Ludwig Maximilian University of Munich with express written informed consent from the subject, who gave written informed consent in accordance with the Declaration of Helsinki. Treatment was given in palliative intent, hence the exemption from ethics committee approval. This registry does not meet the WHO definition of a clinical trial and is considered exempt from http://clinicaltrials.gov requirements.

AUTHOR CONTRIBUTIONS

CE drafted, wrote, and edited the manuscript. N-SH edited and critically revised the manuscript. OR edited the manuscript and figures. MD edited the manuscript. FM edited and critically revised the manuscript for valuable intellectual content.

ACKNOWLEDGMENTS

The case report has not been previously published and is not under consideration elsewhere. The persons listed as authors have given their approval for the submission of the case report.
REFERENCES

1. Pavlidis N. The diagnostic and therapeutic management of leptomeningeal carcinomatosis. *Ann Oncol* (2004) 15(Suppl 4):vi285–91. doi:10.1093/annonc/mdh304.

2. Liao B-C, Lee J-H, Lin C-C, Chen YF, Chang CH, Ho CC, et al. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis. *J Thorac Oncol* (2015) 10(12):1754–61. doi:10.1097/JTO.0000000000000669.

3. Chamberlain MC. Leptomeningeal metastasis. *Curr Opin Oncol* (2010) 22(6):627–35. doi:10.1097/CCO.0b013e32833de986.

4. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. *Cancer* (1982) 49(4):759–72. doi:10.1002/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO;2-7.

5. Groves MD. New strategies in the management of leptomeningeal metastases. *Arch Neurol* (2010) 67(3):305–12. doi:10.1001/archneurol.2010.18.

6. Ozdemir Y, Yildirim BA, Topkan E. Whole brain radiotherapy in management of non-small-cell lung carcinoma associated leptomeningeal carcinoma: evaluation of prognostic factors. *J Neurooncol* (2016) 129(2):329–35. doi:10.1007/s11060-016-2179-9.

7. Brower JV, Saha S, Rosenberg SA, Hullett CR, Ian Robins H. Management of leptomeningeal metastases: prognostic factors and associated outcomes. *J Clin Neurosci* (2016) 27:130–7. doi:10.1016/j.jocn.2015.11.012.

8. Lee SJ, Lee J-I, Nam D-H, Ahn YC, Han JH, Sun JM, et al. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. *J Thorac Oncol* (2013) 8(2):185–91. doi:10.1097/JTO.0b013e3182773f21.

9. Li Y-S, Jiang B-Y, Yang J-J, Tu H-Y, Zhou Q, Guo W-B, et al. Leptomeningeal metastases in non-small cell lung cancer patients with EGFR mutations. *J Thorac Oncol* (2016) 11(11):1962–9. doi:10.1097/JTO.0000000000000629.

10. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. *Lancet Oncol* (2015) 16(2):141–51. doi:10.1016/S1470-2045(14)71173-8.

11. Schuler M, Wu Y-L, Hirsh V, O’Byrne K, Yamamoto N, Mok T, et al. First-line afatinib versus chemotherapy in patients with non–small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. *J Thorac Oncol* (2016) 11(3):380–90. doi:10.1097/JTO.0000000000000708.

12. Attmac A, Al-Batran S-E, Allgäuer M, Jäger E. Afatinib with concurrent radiotherapy in a patient with metastatic non-small cell lung cancer. *Oncol Res Treat* (2014) 37(5):262–5. doi:10.1159/000362488.

13. Li S-H, Hisheh M-H, Fang Y-F. Afatinib in treatment-naive patients with EGFR-mutated lung adenocarcinoma with brain metastasis: a case series. *Medicine (Baltimore)* (2015) 94(41):e1739. doi:10.1097/MD.0000000000001739.

14. Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. *J Thorac Oncol* (2012) 7(2):382–5. doi:10.1097/JTO.0b013e3182398e4f.

15. Soon YL, Leong CN, Koh WY, Tham IWK. EGFR tyrosine kinase inhibitors versus conventional radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis. *Radiother Oncol* (2015) 114(2):167–72. doi:10.1016/j.radonc.2014.12.011.

16. Jiang T, Su C, Li X, Zhao C, Zhou F, Ren S, et al. EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases. *J Thorac Oncol* (2016) 11(10):1718–28. doi:10.1016/j.jtho.2016.05.013.

17. Hoffkenknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schütz M, et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. *J Thorac Oncol* (2015) 10(1):156–63. doi:10.1097/JTO.0000000000000380.

18. Remon J, Majem M. EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to over-coming resistance. *Transl Lung Cancer Res* (2013) 2(6):445–8. doi:10.3978/j.issn.2218-6751.2013.10.14.

19. Zeng YD, Liao H, Qin T, Zhang L, Wei WD, Liang JZ, et al. Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. *Oncotarget* (2015) 6(10):8366–76. doi:10.18632/oncotarget.3187.

20. Zhao J, Chen M, Zhong W, Zhang L, Li L, Xiao Y, et al. Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. *Clin Lung Cancer* (2013) 14(2):188–93. doi:10.1016/j.cllc.2012.06.004.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer, JB, and handling editor declared their shared affiliation, and the handling editor states that the process nevertheless met the standards of a fair and objective review.

Copyright © 2017 Eze, Hegemann, Roengvoraphoj, Dantes and Manapov. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.